*Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda; †Department of Physiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda; ‡Mulago National Referral and Teaching Hospital, Kampala, Uganda; §Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa; ‖Makerere University Joint AIDS Program, Uganda; and ¶School of Medicine, Copperbelt University, Ndola, Zambia.
J Acquir Immune Defic Syndr. 2014 Sep 1;67 Suppl 1:S68-78. doi: 10.1097/QAI.0000000000000259.
With the recent massive scale-up of access to antiretroviral therapy (ART) in resource-limited countries, HIV has become a chronic disease with new challenges. There is mounting evidence of an increased burden of renal and genitourinary diseases among HIV-infected persons caused by direct HIV viral effects and/or indirectly through the development of opportunistic infections, ART medication-related toxicities, and other noncommunicable diseases (NCDs). We review the epidemiology of HIV-associated renal and urogenital diseases, including interactions with kidney-related NCDs such as hypertension, diabetes mellitus, and cardiovascular disease. We also examine the current evidence regarding the impact of HIV infection on the development of urogenital diseases. Highly advisable in sub-Saharan Africa are the establishment of renal disease registries, reviews of existing clinical practice including cost-effectiveness studies, and the adoption and use of HIV-related NCD management, with training for different cadres of health providers. Epidemiological research priorities include prospective studies to evaluate the true prevalence and spectrum of HIV-related renal disease and their progression. Simple diagnostics tools should be evaluated, including urinary dipsticks and point-of-care urea and creatinine tests to screen for kidney injury in primary care settings. Study of urological manifestations of HIV can help determine the extent of disease and outcomes. As patients live longer on ART, the burden of renal and genitourological complications of HIV and of ART can be expected to increase with a commensurate urgency in both discovery and evidence-based improvements in clinical management.
随着资源有限国家抗逆转录病毒疗法 (ART) 的大规模普及,HIV 已成为一种慢性病,带来了新的挑战。越来越多的证据表明,HIV 感染者的肾脏和泌尿生殖系统疾病负担增加,这是由 HIV 病毒的直接作用以及通过机会性感染、ART 药物相关毒性和其他非传染性疾病 (NCDs) 的发展而间接引起的。我们回顾了 HIV 相关肾脏和泌尿生殖系统疾病的流行病学,包括与高血压、糖尿病和心血管疾病等与肾脏相关的 NCD 的相互作用。我们还检查了 HIV 感染对泌尿生殖系统疾病发展影响的现有证据。在撒哈拉以南非洲地区,强烈建议建立肾脏疾病登记处,审查现有的临床实践,包括成本效益研究,并采用和使用与 HIV 相关的 NCD 管理方法,对不同级别的卫生保健提供者进行培训。流行病学研究重点包括前瞻性研究,以评估 HIV 相关肾脏疾病的真实患病率和谱及其进展。应评估简单的诊断工具,包括尿液试纸和即时尿素和肌酐检测,以在初级保健环境中筛查肾脏损伤。研究 HIV 的泌尿系统表现可以帮助确定疾病的严重程度和结果。随着患者在 ART 上的存活时间更长,预计 HIV 肾脏和泌尿生殖系统并发症以及 ART 的负担会增加,因此迫切需要发现和基于证据的临床管理改善。